
Eyestem Presents Interim Phase 2 Data for Eyecyte-RPE™ at EURetina 2026 Conference, Showing Continuing Visual Acuity Gains in Geographic Atrophy
India, 05 October 2026: Eyestem Research Private Limited, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, announced promising clinical findings from its randomized Phase 2 clinical trial of Eyecyte-RPE™ for Geographic Atrophy (GA) secondary to dry age-related macular degeneration (AMD).

The interim results were presented by Dr. Ritesh Narula, Co-Principal Investigator of the trial, at EURetina 2026 in Vienna, Austria.
With the Phase 2 trial progressing, Eyestem is ready to file for its US Investigational New Drug (IND) application in early 2027 for treating Geographic Atrophy and related vision loss.
The randomized controlled Phase 2 trial has recruited 24 subjects, with 15 in the treatment arm and 9 in the natural history control arm.
Eyecyte-RPE™ has shown an excellent overall safety profile in the Phase 2 study consistent with the safety profile in the preceding Phase 1 clinical trial. Seven different surgeons have performed these surgeries using Eyestem’s patent-pending surgical technique.
The visual acuity gains observed in Phase 1 have continued with longer follow-up. Seven subjects have shown an improvement of 13 letters at 12 months follow-up vs. baseline, while four subjects who completed 18 months have maintained an improvement of 15.3 letters.
Eyestem Research Submits IND Approval Application for Groundbreaking AMD Therapy
The visual acuity gains observed in Phase 2 are consistent with those seen in Phase 1, with three subjects who completed six months of follow-up demonstrating a 16-letter gain vs. baseline. 12 subjects completed 6 months across both phases with an average improvement of 13.8 letters.
Commenting on the clinical progress, Dr. Jogin Desai, Founder and CEO, Eyestem, said, “Early results from the Phase 2 clinical study build on the highly promising Phase 1 results, achieving an important milestone for Eyestem’s geographic atrophy program. We are encouraged to see the gains sustained over longer follow-up periods coupled with a good safety profile. Together, these findings give us greater confidence in the potential of Eyecyte-RPE™ to meaningfully change the treatment landscape for patients with geographic atrophy across the world.”
For more information, please visit: https://clinicaltrials.gov/study/NCT06394232
About Eyecyte-RPE™
Eyecyte-RPE™, derived from human induced pluripotent stem cells (hiPSCs), is Eyestem’s proprietary retinal cell therapy product with a novel composition, developed and patented by Eyestem Research. The product can help replace the damaged or lost retinal pigment epithelial (RPE) cells and potentially enable tissue regeneration in the diseased retina. This unique formulation is allogeneic, scalable, and can be stored as a frozen vial for long periods of time.
About Geographic Atrophy
Dry AMD is the leading cause of blindness for people over 50. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible loss of central vision, characterised by the death of cells in the macula, the central part of the retina. Approximately 196 million people suffer from dry AMD globally, five million of whom suffer from GA.
About Eyestem Research Headquartered in Bangalore and Delaware, Eyestem Research is a clinical-stage biotechnology company, which was started by a founding team with several decades of experience in pharmaceutical product development, retinal surgery, and cell biology. It has won significant accolades with the most recent one being named the top innovator in India across all sectors in 2022 by the prestigious The Economic Times newspaper. It is also the recipient of several prestigious grants and awards from the Department of Biotechnology (DBT), Government of India, and has been feted at high-profile government events as one of the most successful and innovative biotechnology companies in the country.
India, 05 October 2026: Eyestem Research Private Limited, a pioneering biotechnology company developing advanced scalable cell therapy solutions for blindness caused by dry age-related macular degeneration, announced promising clinical findings from its randomized Phase 2 clinical trial of Eyecyte-RPE™ for Geographic Atrophy (GA) secondary to dry age-related macular degeneration (AMD). The interim results were presented by Dr. Ritesh Narula, Co-Principal Investigator of the trial, at EURetina 2026 in Vienna, Austria. With the Phase 2 trial progressing, Eyestem is ready to file for its US Investigational New Drug (IND) application in early 2027 for treating Geographic Atrophy and related vision loss.
The randomized controlled Phase 2 trial has recruited 24 subjects, with 15 in the treatment arm and 9 in the natural history control arm.
Eyecyte-RPE™ has shown an excellent overall safety profile in the Phase 2 study consistent with the safety profile in the preceding Phase 1 clinical trial. Seven different surgeons have performed these surgeries using Eyestem’s patent-pending surgical technique.
The visual acuity gains observed in Phase 1 have continued with longer follow-up. Seven subjects have shown an improvement of 13 letters at 12 months follow-up vs. baseline, while four subjects who completed 18 months have maintained an improvement of 15.3 letters.
The visual acuity gains observed in Phase 2 are consistent with those seen in Phase 1, with three subjects who completed six months of follow-up demonstrating a 16-letter gain vs. baseline. 12 subjects completed 6 months across both phases with an average improvement of 13.8 letters.
Commenting on the clinical progress, Dr. Jogin Desai, Founder and CEO, Eyestem, said, “Early results from the Phase 2 clinical study build on the highly promising Phase 1 results, achieving an important milestone for Eyestem’s geographic atrophy program. We are encouraged to see the gains sustained over longer follow-up periods coupled with a good safety profile. Together, these findings give us greater confidence in the potential of Eyecyte-RPE™ to meaningfully change the treatment landscape for patients with geographic atrophy across the world.”
For more information, please visit: https://clinicaltrials.gov/study/NCT06394232
About Eyecyte-RPE™
Eyecyte-RPE™, derived from human induced pluripotent stem cells (hiPSCs), is Eyestem’s proprietary retinal cell therapy product with a novel composition, developed and patented by Eyestem Research. The product can help replace the damaged or lost retinal pigment epithelial (RPE) cells and potentially enable tissue regeneration in the diseased retina. This unique formulation is allogeneic, scalable, and can be stored as a frozen vial for long periods of time.
About Geographic Atrophy
Dry AMD is the leading cause of blindness for people over 50. Geographic atrophy (GA) is an advanced form of dry age-related macular degeneration (AMD) that leads to progressive and irreversible loss of central vision, characterised by the death of cells in the macula, the central part of the retina. Approximately 196 million people suffer from dry AMD globally, five million of whom suffer from GA.
About Eyestem Research Headquartered in Bangalore and Delaware, Eyestem Research is a clinical-stage biotechnology company, which was started by a founding team with several decades of experience in pharmaceutical product development, retinal surgery, and cell biology. It has won significant accolades with the most recent one being named the top innovator in India across all sectors in 2022 by the prestigious The Economic Times newspaper. It is also the recipient of several prestigious grants and awards from the Department of Biotechnology (DBT), Government of India, and has been feted at high-profile government events as one of the most successful and innovative biotechnology companies in the country.
Latest Posts
- Solmate Infrastructure Plans to Expand into Global AI Compute with a GPU-as -a-Service asset-light Model 16 Nov 2026
- Estonia-Russia border closed From December 1 After Foiled Arson Attack on Drone Factory16 Nov 2026
- Amazon Loses 40 Satellites After Vulcan Rocket Fails During Launch16 Nov 2026
- What Did Former Pakistan PM Imran Khan Tell Pakistan’s Top Judges About His Health16 Nov 2026
- West Bengal Moves Supreme Court Against Calcutta High Court Stay on Kolkata Municipal Corporation Elections16 Nov 2026
- Adani Group Begins Production Of India’s Longest Wind Turbine Blade At Mundra16 Nov 2026
- Xi Jinping, Donald Trump and Vladimir Putin to Hold First Trilateral Summit in Shenzhen – China on November 1916 Nov 2026
- Encounter Breaks Out in Kulgam, Jammu Kashmir After Security Forces Launch Search Operation16 Nov 2026
- High Court Seeks Time-Bound Plan to Fill 6,775 Health Department Vacancies In Jammu Kashmir16 Nov 2026
- Iran Learning From Last War, Moving Towards Major Cyber Operations !!15 Nov 2026
